PUNE, India, May 30, 2017 /PRNewswire/ --
RnRMarketResearch.com adds "Aspergillosis - Pipeline Review, H1 2017" therapeutic market research report of 101 pages with latest updates, data and information to its online business intelligence library.
The report "Aspergillosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Aspergillosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.
Complete report on Aspergillosis - Pipeline Review, H1 2017 spread across 101 pages is available at http://www.rnrmarketresearch.com/aspergillosis-pipeline-review-h1-2017-market-report.html
Aspergillosis (Infectious Disease) pipeline guide reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 5, 19 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively. Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies discussed in this report include Amplyx Pharmaceuticals Inc, Astellas Pharma Inc, Biomar Microbial Technologies, Biosergen AS, Cidara Therapeutics Inc, F2G Ltd, Hsiri Therapeutics LLC, iCo Therapeutics Inc., Matinas BioPharma Holdings Inc, Merck & Co Inc, Nanomerics Ltd, Novabiotics Ltd, Pulmatrix Inc, Pulmocide Ltd, Scynexis Inc, Sealife PHARMA GMBH, Sigma-Tau SpA, Vical Inc, Visterra Inc
Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1019676. (This report is available at up to 25% Discount till June 02nd 2017.)
Drug Profiles Discussed In Report amphotericin B, Amphotericin B sodium, APX-001, APX-001A, ASP-9726, Aspergillus fumigatus vaccine=, BSG-005, C-001, C-016, CD-101, celastrol, Cellullar Immunotherapy for Viral Infections and Fungal Infections, F-901318, itraconazole, KB-425796C, MDN-0018, NP-339, PC-945, posaconazole, PTX-3, SCY-078, SLP-0901, SLP-0904, Small Molecule for Aspergillosis, Small Molecules for Aspergillosis and Candidiasis, Small Molecules for Fungal Infections, Small Molecules for Fungal Infections, Small Molecules for Invasive Aspergillosis, Vaccine to Target Glucosylceramide for Fungal Infections, VIS-FNG, VL-2397
Related reports on Aspergillosis:
Aspergillosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
"Aspergillosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Aspergillosis Report is to understand the market and pipeline status of the drugs around the Aspergillosis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Aspergillosis. While the leading brands, companies and chemicals are considered thoroughly, report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.
Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.
About Us:
RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.
Contact: Ritesh Tiwari 2nd Floor, Metropole, Bund Garden Road, Pune - 411001, India Tel: +1-888-391-5441 E-mail: [email protected]
SOURCE RnRMarketResearch
Advertisement
RnRMarketResearch.com adds "Aspergillosis - Pipeline Review, H1 2017" therapeutic market research report of 101 pages with latest updates, data and information to its online business intelligence library.
Advertisement
The report "Aspergillosis - Pipeline Review, H1 2017" provides comprehensive information on the therapeutics under development for Aspergillosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.
Complete report on Aspergillosis - Pipeline Review, H1 2017 spread across 101 pages is available at http://www.rnrmarketresearch.com/aspergillosis-pipeline-review-h1-2017-market-report.html
Aspergillosis (Infectious Disease) pipeline guide reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 2, 5, 19 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 3 molecules, respectively. Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies discussed in this report include Amplyx Pharmaceuticals Inc, Astellas Pharma Inc, Biomar Microbial Technologies, Biosergen AS, Cidara Therapeutics Inc, F2G Ltd, Hsiri Therapeutics LLC, iCo Therapeutics Inc., Matinas BioPharma Holdings Inc, Merck & Co Inc, Nanomerics Ltd, Novabiotics Ltd, Pulmatrix Inc, Pulmocide Ltd, Scynexis Inc, Sealife PHARMA GMBH, Sigma-Tau SpA, Vical Inc, Visterra Inc
Order a copy of this research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=1019676. (This report is available at up to 25% Discount till June 02nd 2017.)
Drug Profiles Discussed In Report amphotericin B, Amphotericin B sodium, APX-001, APX-001A, ASP-9726, Aspergillus fumigatus vaccine=, BSG-005, C-001, C-016, CD-101, celastrol, Cellullar Immunotherapy for Viral Infections and Fungal Infections, F-901318, itraconazole, KB-425796C, MDN-0018, NP-339, PC-945, posaconazole, PTX-3, SCY-078, SLP-0901, SLP-0904, Small Molecule for Aspergillosis, Small Molecules for Aspergillosis and Candidiasis, Small Molecules for Fungal Infections, Small Molecules for Fungal Infections, Small Molecules for Invasive Aspergillosis, Vaccine to Target Glucosylceramide for Fungal Infections, VIS-FNG, VL-2397
Related reports on Aspergillosis:
Aspergillosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
"Aspergillosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Aspergillosis Report is to understand the market and pipeline status of the drugs around the Aspergillosis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Aspergillosis. While the leading brands, companies and chemicals are considered thoroughly, report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.
Explore more reports of Therapeutics Market Research at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics.
About Us:
RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.
Contact: Ritesh Tiwari 2nd Floor, Metropole, Bund Garden Road, Pune - 411001, India Tel: +1-888-391-5441 E-mail: [email protected]
SOURCE RnRMarketResearch
